HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPACT THERAP-B

13.460

+1.31010.78%

Volume:829.29K

Turnover:10.91M

Market Cap:3.80B

PE:-8.91

High:13.500

Open:12.120

Low:12.120

Close:12.150

52wk High:47.980

52wk Low:10.310

Shares:282.46M

HK Float Shares:282.46M

Volume Ratio:1.28

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.511

ROE:--

ROA:-40.35%

PB:-3.40

PE(LYR):-8.91

PS:85.18

Loading ...

Overview Company News Filings

IMPACT THERAP-B (07630) Set to Join Hang Seng Composite Index, Paving Way for Stock Connect Inclusion

IMPACT Therapeutics Sets 31 Aug 2026 Board Meeting to Approve H1 2026 Unaudited Results

Bulletin Express

Impact Therapeutics Schedules Board Meeting to Review Interim Results

Hong Kong Stock Market Moves: IMPACT THERAP-B Rises Over 3% on Expected Interim Loss Reduction and IMP2794 PCC Nomination

IMPACT THERAP-B Designates IMP2794 as Preclinical Candidate, a Highly Selective KAT6A PROTAC from Its Proprietary Platform

Impact Therapeutics Names Imp2794 KAT6A Protac Degrader as Preclinical Candidate

Impact Therapeutics - Announces Imp2794 as Kat6a-Specific Preclinical Candidate

THOMSON REUTERS

IMPACT Therapeutics forecasts 276%–359% revenue surge and narrower interim loss

Bulletin Express

Impact Therapeutics - Expects Revenue of Rmb94.7 Mln-Rmb115.7 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Impact Therapeutics Expects H1 Loss to Narrow to RMB 81.7 Million-RMB 99.9 Million

IMPACT Therapeutics Maintains 282.46 Million Issued H Shares and Confirms Public Float Compliance for July 2026

Bulletin Express

Hong Kong Stock Moves | <b>IMPACT THERAP-B</b> (07630) Plunges Over 13% in Afternoon Trade, Down Nearly 70% Since Early July, Total Market Cap Falls Below HK$3.5 Billion

Impact Therapeutics Licenses Senaparib Rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 Million

IMPACT THERAP-B Surges Over 11% in Early Trading Following Exclusive Licensing Deal for Cancer Drug Senaparib

IMPACT Therapeutics, Inc. Secures EUR423.50 Million Licensing Deal With Pharmanovia for Senaparib Across 66 Countries

Bulletin Express

Impact Therapeutics Signs Exclusive License Deal with Pharmanovia for Senaparib in Europe, Others

Impact Therapeutics - Eligible for up to EUR 423.50 Mln Plus Tiered Royalties in Pharmanovia Deal

THOMSON REUTERS

Impact Therapeutics - Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

THOMSON REUTERS

Impact Therapeutics Shareholders Approve Articles of Association Amendments

Impact Therapeutics Nominates Preclinical Candidate for GI Cancers

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/07630/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":13.46,"timestamp":1787299687168,"preClose":12.15,"halted":0,"volume":829286,"delay":0,"changeRate":0.1078189300411523,"floatShares":282461530,"shares":282461530,"eps":-1.5107867902986771,"marketStatus":"Market Closed","change":1.31,"latestTime":"08-21 16:08:07","open":12.12,"high":13.5,"low":12.12,"amount":10914574,"amplitude":0.11358,"askPrice":13.46,"askSize":4000,"bidPrice":13.26,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-1.3535895364975807,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.15,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.282420597499764,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.510787,"volumeRatio":1.282420597499764,"shares":282461530,"dividePrice":0,"high":13.5,"amplitude":0.11358,"preClose":12.15,"low":12.12,"week52Low":10.31,"pbRate":"-3.40","psRate":"85.18","week52High":47.98,"institutionHeld":0,"latestPrice":13.46,"committee":-0.73913,"eps":-1.5107867902986771,"divideRate":0,"volume":829286,"delay":0,"ttmEps":-1.3535895364975807,"open":12.12,"prevYearClose":20.1,"prevWeekClose":12.84,"prevMonthClose":13.23,"prevQuarterClose":36.08,"fiveDayClose":12.84,"twentyDayClose":11.5,"sixtyDayClose":37.74,"earningDate":1788105600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782230400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-08-21","current":-9.94393,"percent":0.681159,"low":-34.323153,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"high":-8.821219,"avg":-20.607242,"sd":9.633676,"marketCap":3717182649},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649}],"updateTime":1787463870454},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165050593","title":"IMPACT THERAP-B (07630) Set to Join Hang Seng Composite Index, Paving Way for Stock Connect Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1165050593","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165050593?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:02","pubTimestamp":1787313754,"startTime":"0","endTime":"0","summary":"On August 21, 2026, Hang Seng Indexes Company unveiled the results of its quarterly index review as of June 30, 2026, with IMPACT THERAP-B (07630) being added to the Hang Seng Composite Index. The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","HSCI","FLHK","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122709213","title":"IMPACT Therapeutics Sets 31 Aug 2026 Board Meeting to Approve H1 2026 Unaudited Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1122709213","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122709213?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:47","pubTimestamp":1787129230,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc announced that its board of directors will convene on 31 August 2026 to review and approve the unaudited interim financial results for the six months ended 30 June 2026. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456604","title":"Impact Therapeutics Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456604?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:38","pubTimestamp":1787128710,"startTime":"0","endTime":"0","summary":"Impact Therapeutics schedules board meeting to review interim resultsImpact Therapeutics scheduled a board meeting for Aug. 31, 2026 to review unaudited interim results for the six months ended June 3","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL59SYZv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162268658","title":"Hong Kong Stock Market Moves: IMPACT THERAP-B Rises Over 3% on Expected Interim Loss Reduction and IMP2794 PCC Nomination","url":"https://stock-news.laohu8.com/highlight/detail?id=1162268658","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162268658?lang=en_us&edition=fundamental","pubTime":"2026-08-14 13:52","pubTimestamp":1786686736,"startTime":"0","endTime":"0","summary":"Shares of IMPACT THERAP-B (07630) climbed more than 3% in early trading, last up 2.64% at HKD 12.43, with a turnover of approximately HKD 3.06 million.On the news front, IMPACT THERAP-B recently...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","PPC","BK4588","VXUS","BK4585","BK4212","BK1161","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133174395","title":"IMPACT THERAP-B Designates IMP2794 as Preclinical Candidate, a Highly Selective KAT6A PROTAC from Its Proprietary Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1133174395","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133174395?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:20","pubTimestamp":1786526417,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that it has designated IMP2794 as a preclinical candidate compound (PCC), a KAT6A-specific degrader PROTAC discovered through its proprietary targeted protein...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197808","title":"Impact Therapeutics Names Imp2794 KAT6A Protac Degrader as Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197808","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:16","pubTimestamp":1786526190,"startTime":"0","endTime":"0","summary":"Impact Therapeutics names IMP2794 KAT6A PROTAC degrader as preclinical candidateImpact Therapeutics nominated IMP2794 as a preclinical candidate, its first from a proprietary targeted protein degradat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL41R3kz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978702","title":"Impact Therapeutics - Announces Imp2794 as Kat6a-Specific Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978702?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:16","pubTimestamp":1786526175,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128234712","title":"IMPACT Therapeutics forecasts 276%–359% revenue surge and narrower interim loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1128234712","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128234712?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:47","pubTimestamp":1786438029,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. issued a profit alert for the six months ended 30 June 2026, projecting a sharp top-line expansion and a materially reduced loss versus the prior-year period. Revenue is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899329","title":"Impact Therapeutics - Expects Revenue of Rmb94.7 Mln-Rmb115.7 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899329?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:41","pubTimestamp":1786437675,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658937129","title":"Impact Therapeutics Expects H1 Loss to Narrow to RMB 81.7 Million-RMB 99.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658937129","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658937129?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:41","pubTimestamp":1786437668,"startTime":"0","endTime":"0","summary":"Impact Therapeutics expects H1 loss to narrow to RMB 81.7 million-RMB 99.9 millionImpact Therapeutics guided for revenue of RMB 94.7-115.7 million for the six months ended June 30, 2026, up 276%-359%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLbw6wN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103430874","title":"IMPACT Therapeutics Maintains 282.46 Million Issued H Shares and Confirms Public Float Compliance for July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1103430874","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103430874?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:28","pubTimestamp":1785922107,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (H shares) filed its Monthly Return for the period ended 31 July 2026, confirming that the company’s equity structure remained unchanged during the month. • Authorised and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147623174","title":"Hong Kong Stock Moves | <b>IMPACT THERAP-B</b> (07630) Plunges Over 13% in Afternoon Trade, Down Nearly 70% Since Early July, Total Market Cap Falls Below HK$3.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1147623174","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147623174?lang=en_us&edition=fundamental","pubTime":"2026-08-03 14:12","pubTimestamp":1785737537,"startTime":"0","endTime":"0","summary":"According to financial information, IMPACT THERAP-B (07630) fell over 13% in the afternoon session. As of the time of writing, it was down 12.47% to HK$11.58, with a turnover of HK$5.2774 million. On...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","BK1161","BK4585","VXUS","BK4588","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656328122","title":"Impact Therapeutics Licenses Senaparib Rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656328122","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656328122?lang=en_us&edition=fundamental","pubTime":"2026-08-03 13:58","pubTimestamp":1785736690,"startTime":"0","endTime":"0","summary":"Impact Therapeutics licenses senaparib rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 millionImpact Therapeutics signed an exclusive license deal wi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLpsGXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140891841","title":"IMPACT THERAP-B Surges Over 11% in Early Trading Following Exclusive Licensing Deal for Cancer Drug Senaparib","url":"https://stock-news.laohu8.com/highlight/detail?id=1140891841","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140891841?lang=en_us&edition=fundamental","pubTime":"2026-07-31 09:54","pubTimestamp":1785462854,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) saw its share price climb more than 11% in early trading, reaching a high of HK$12.79, representing an 11.02% gain, with trading volume reaching HK$996,900.On July 30, the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107391797","title":"IMPACT Therapeutics, Inc. Secures EUR423.50 Million Licensing Deal With Pharmanovia for Senaparib Across 66 Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=1107391797","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107391797?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:24","pubTimestamp":1785407093,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has entered into an exclusive agreement with global specialty pharmaceutical company Pharmanovia to manufacture, develop and commercialise the PARP1/2 inhibitor senaparib in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878714","title":"Impact Therapeutics Signs Exclusive License Deal with Pharmanovia for Senaparib in Europe, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878714","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878714?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:21","pubTimestamp":1785406891,"startTime":"0","endTime":"0","summary":"BRIEF-IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, OthersJuly 30 (Reuters)-IMPACT Therapeutics Inc7630.HK:EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878268","title":"Impact Therapeutics - Eligible for up to EUR 423.50 Mln Plus Tiered Royalties in Pharmanovia Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878268?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:18","pubTimestamp":1785406701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782548","title":"Impact Therapeutics - Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655782548?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:17","pubTimestamp":1785406678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011467","title":"Impact Therapeutics Shareholders Approve Articles of Association Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011467","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654011467?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:48","pubTimestamp":1785149311,"startTime":"0","endTime":"0","summary":"Impact Therapeutics shareholders approve articles of association amendmentsImpact Therapeutics shareholders adopted amendments to the articles of association at a July 27, 2026 extraordinary general m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8Rp10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654092639","title":"Impact Therapeutics Nominates Preclinical Candidate for GI Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2654092639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654092639?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:28","pubTimestamp":1785133700,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  nominated IMP3201, a CEACAM5-targeted dual-payload antibody-drug conjugate , as a preclinical candidate.IMP3201 is the first preclinical candidate developed using its proprietary dual-payload ADC platform, according to a Monday Hong Kong bourse filing. It is being developed to treat gastrointestinal cancers, including colorectal, pancreatic, gastric and esophageal squamous cell carcinoma.Shares of the company fell over 6% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4080","BK7095","BK4231","BK4539","ADC.AU","LENZ","NETL","07630","ADC","BK4007","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}]}}